Literature DB >> 18806919

Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.

Christoph Laske1, Elke Stransky, Andreas Fritsche, Gerhard W Eschweiler, Thomas Leyhe.   

Abstract

Hypercortisolemia and increased levels of hyperphosphorylated tau proteins in cerebrospinal fluid (CSF) are common features with pathogenic relevance in Alzheimer;s disease (AD). Experimental studies point to an influence of cortisol on Abeta and tau pathology in AD. Association of both parameters have not yet been described in a sample of AD patients. In the present study, serum levels of cortisol were determined in 26 patients with mild AD dementia and 20 age-matched healthy elderly controls by ELISA. In addition, we measured in AD patients CSF levels of cortisol, total tau (T-tau), tau phosphorylated at threonine 181 (P-tau 181), tau protein phosphorylated at threonine 231 (P-tau 231) and beta-Amyloid (Abeta) 1-42 and determined T-tau/Abeta 1-42 ratios in CSF. We found in AD patients significantly increased cortisol serum levels (551.4 +/- 146.1 nmol/l; P = 0.002) as compared to healthy controls (435.3 +/- 83.9 nmol/l). In AD patients, cortisol serum levels were significantly inversely correlated with T-tau (r = -0.496; P = 0.01), P-tau 181 (r = -0.558; P = 0.003) and P-tau 231 (-0.500; P = 0.009) protein levels and T-tau/Abeta 1-42 ratios (r = -0.450; P = 0.021) in CSF. In addition, cortisol serum levels showed a trend of positive correlation with Abeta 1-42 CSF levels (r = 0.386; P = 0.052). However, no significant correlations of cortisol serum with CSF levels as well as cortisol CSF levels with CSF biomarkers could be detected in AD patients. In conclusion, our results show that increased cortisol serum but not CSF levels are associated with minor signs of AD pathology in CSF, indicating a putative neuroprotective effect of moderately elevated cortisol serum levels in patients with mild AD dementia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806919     DOI: 10.1007/s00406-008-0838-3

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  27 in total

1.  Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease.

Authors:  Kim N Green; Lauren M Billings; Benno Roozendaal; James L McGaugh; Frank M LaFerla
Journal:  J Neurosci       Date:  2006-08-30       Impact factor: 6.167

2.  Increased levels of adrenocortical and gonadal hormones in mild to moderate Alzheimer's disease.

Authors:  Sigbritt Rasmuson; Birgitta Näsman; Kjell Carlström; Tommy Olsson
Journal:  Dement Geriatr Cogn Disord       Date:  2002       Impact factor: 2.959

3.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

4.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Authors:  Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

Review 5.  Action of glucocorticoids on survival of nerve cells: promoting neurodegeneration or neuroprotection?

Authors:  I M Abrahám; T Harkany; K M Horvath; P G Luiten
Journal:  J Neuroendocrinol       Date:  2001-09       Impact factor: 3.627

6.  CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.

Authors:  E Kapaki; G P Paraskevas; I Zalonis; C Zournas
Journal:  Eur J Neurol       Date:  2003-03       Impact factor: 6.089

7.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Authors:  Oskar Hansson; Henrik Zetterberg; Peder Buchhave; Elisabet Londos; Kaj Blennow; Lennart Minthon
Journal:  Lancet Neurol       Date:  2006-03       Impact factor: 44.182

8.  Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease.

Authors:  L M Bierer; P R Hof; D P Purohit; L Carlin; J Schmeidler; K L Davis; D P Perl
Journal:  Arch Neurol       Date:  1995-01

9.  Cortisol and Alzheimer's disease, I: Basal studies.

Authors:  K L Davis; B M Davis; B S Greenwald; R C Mohs; A A Mathé; C A Johns; T B Horvath
Journal:  Am J Psychiatry       Date:  1986-03       Impact factor: 18.112

10.  Dementia of the Alzheimer type and hypothalamus-pituitary-adrenocortical axis: changes in cerebrospinal fluid corticotropin releasing factor and plasma cortisol levels.

Authors:  E Martignoni; F Petraglia; A Costa; G Bono; A R Genazzani; G Nappi
Journal:  Acta Neurol Scand       Date:  1990-05       Impact factor: 3.209

View more
  17 in total

1.  Alzheimer disease: blood-based biomarkers in AD--a silver lining on the horizon.

Authors:  Christoph Laske
Journal:  Nat Rev Neurol       Date:  2012-08-14       Impact factor: 42.937

2.  Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.

Authors:  Holly D Soares; William Z Potter; Eve Pickering; Max Kuhn; Frederick W Immermann; David M Shera; Mats Ferm; Robert A Dean; Adam J Simon; Frank Swenson; Judith A Siuciak; June Kaplow; Madhav Thambisetty; Panayiotis Zagouras; Walter J Koroshetz; Hong I Wan; John Q Trojanowski; Leslie M Shaw
Journal:  Arch Neurol       Date:  2012-10

Review 3.  Aberrant expression of RCAN1 in Alzheimer's pathogenesis: a new molecular mechanism and a novel drug target.

Authors:  Yili Wu; Philip T T Ly; Weihong Song
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

4.  Intranasal insulin increases regional cerebral blood flow in the insular cortex in men independently of cortisol manipulation.

Authors:  Thomas M Schilling; Diana S Ferreira de Sá; René Westerhausen; Florian Strelzyk; Mauro F Larra; Manfred Hallschmid; Egemen Savaskan; Melly S Oitzl; Hans-Peter Busch; Ewald Naumann; Hartmut Schächinger
Journal:  Hum Brain Mapp       Date:  2013-08-01       Impact factor: 5.038

5.  Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort.

Authors:  Wang Cong; Xianglian Meng; Jin Li; Qiushi Zhang; Feng Chen; Wenjie Liu; Ying Wang; Sipu Cheng; Xiaohui Yao; Jingwen Yan; Sungeun Kim; Andrew J Saykin; Hong Liang; Li Shen
Journal:  BMC Genomics       Date:  2017-05-30       Impact factor: 3.969

Review 6.  Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review.

Authors:  Erwin Lemche
Journal:  Curr Genomics       Date:  2018-11       Impact factor: 2.236

7.  The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease.

Authors:  Craig W Ritchie; Karen Ritchie
Journal:  BMJ Open       Date:  2012-11-19       Impact factor: 2.692

8.  Metabolite profiling of Alzheimer's disease cerebrospinal fluid.

Authors:  Christian Czech; Peter Berndt; Kristina Busch; Oliver Schmitz; Jan Wiemer; Veronique Most; Harald Hampel; Jürgen Kastler; Hans Senn
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

9.  Plasma cortisol in Alzheimer's disease with or without depressive symptoms.

Authors:  Martina Zvěřová; Zdeněk Fišar; Roman Jirák; Eva Kitzlerová; Jana Hroudová; Jiří Raboch
Journal:  Med Sci Monit       Date:  2013-08-19

10.  Inflammatory process in Alzheimer's Disease.

Authors:  Marco A Meraz-Ríos; Danira Toral-Rios; Diana Franco-Bocanegra; Juana Villeda-Hernández; Victoria Campos-Peña
Journal:  Front Integr Neurosci       Date:  2013-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.